{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:05:13Z","timestamp":1785888313484,"version":"3.56.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"vor","delay-in-days":1783,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2016]]},"DOI":"10.1136\/esmoopen-2015-000003","type":"journal-article","created":{"date-parts":[[2016,11,11]],"date-time":"2016-11-11T14:09:56Z","timestamp":1478873396000},"page":"e000003","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis"],"prefix":"10.1016","volume":"1","author":[{"given":"D.","family":"Jenni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.B.","family":"Karpova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"M\u00fchleisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mangana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Dreier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hafner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 61","key":"10.1136\/esmoopen-2015-000003_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2133.146.s61.2.x","article-title":"The epidemiology of skin cancer","volume":"146","author":"Diepgen","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1136\/esmoopen-2015-000003_bb0015","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMra022137","article-title":"Skin cancers after organ transplantation","volume":"348","author":"Euvrard","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2015-000003_bb0020","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S1470-2045(08)70178-5","article-title":"Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study","volume":"9","author":"Brantsch","year":"2008","journal-title":"Lancet Oncol"},{"issue":"Suppl 5","key":"10.1136\/esmoopen-2015-000003_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2011.04296.x","article-title":"Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma and precursor lesions","volume":"25","author":"Bonerandi","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1136\/esmoopen-2015-000003_bb0030","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Basal cell and squamous cell skin cancers. National Comprehensive Cancer Network; Version 2. 2012. http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#site"},{"key":"10.1136\/esmoopen-2015-000003_bb0035","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000337027","article-title":"Long-term recurrence rate of large and difficult to treat cutaneous squamous cell carcinomas after superficial radiotherapy","volume":"224","author":"Barysch","year":"2012","journal-title":"Dermatology (Basel)"},{"key":"10.1136\/esmoopen-2015-000003_bb0040","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1634\/theoncologist.2009-0210","article-title":"Treatment of unresectable and metastatic cutaneous squamous cell carcinoma","volume":"15","author":"Cranmer","year":"2010","journal-title":"Oncologist"},{"key":"10.1136\/esmoopen-2015-000003_bb0045","doi-asserted-by":"crossref","first-page":"S369","DOI":"10.1097\/JTO.0b013e31826defaa","article-title":"Update on HER1\u20133 in advanced non-small-cell lung cancer","volume":"7","author":"Horn","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1136\/esmoopen-2015-000003_bb0050","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1586\/17474124.2014.844648","article-title":"The role of epidermal growth factor receptor in prognosis and treatment of gastric cancer","volume":"8","author":"Hong","year":"2014","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"Suppl 4","key":"10.1136\/esmoopen-2015-000003_bb0055","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S0959-8049(01)00233-7","article-title":"The EGFR as a target for anticancer therapy\u2014focus on cetuximab","volume":"37","author":"Baselga","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1136\/esmoopen-2015-000003_bb0060","first-page":"1459","article-title":"Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor","volume":"7","author":"Ciardiello","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1136\/esmoopen-2015-000003_bb0065","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ctrv.2013.10.002","article-title":"Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC)","volume":"40","author":"Cohen","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1136\/esmoopen-2015-000003_bb0070","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.prp.2011.03.002","article-title":"Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy","volume":"207","author":"Uribe","year":"2011","journal-title":"Pathol Res Pract"},{"key":"10.1136\/esmoopen-2015-000003_bb0075","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1345\/aph.1G387","article-title":"Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors","volume":"40","author":"Nelson","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1136\/esmoopen-2015-000003_bb0080","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/978-3-642-54490-3_7","article-title":"Lapatinib","volume":"201","author":"Nolting","year":"2014","journal-title":"Recent Results Cancer Res"},{"key":"10.1136\/esmoopen-2015-000003_bb0085","doi-asserted-by":"crossref","first-page":"6255","DOI":"10.1038\/sj.onc.1205794","article-title":"Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR\/erbB2 and downstream Erk1\/2 and AKT pathways","volume":"21","author":"Xia","year":"2002","journal-title":"Oncogene"},{"key":"10.1136\/esmoopen-2015-000003_bb0090","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s11864-014-0280-x","article-title":"Therapy of advanced squamous cell carcinoma of the skin","volume":"15","author":"Bejar","year":"2014","journal-title":"Curr Treat Options Oncol"},{"key":"10.1136\/esmoopen-2015-000003_bb0095","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1038\/jid.2013.115","article-title":"Hypoxia contributes to melanoma heterogeneity by triggering HIF1alpha-dependent phenotype switching","volume":"133","author":"Widmer","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1136\/esmoopen-2015-000003_bb0100","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1158\/1078-0432.CCR-09-1766","article-title":"Mitogen-activated protein\/extracellular signal-regulated kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders","volume":"16","author":"Schad","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1136\/esmoopen-2015-000003_bb0105","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2133.2006.07603.x","article-title":"Characterization of the expression and activation of the epidermal growth factor receptor in squamous cell carcinoma of the skin","volume":"156","author":"Fogarty","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1136\/esmoopen-2015-000003_bb0110","first-page":"909","article-title":"Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors","volume":"20","author":"Peuvrel","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1136\/esmoopen-2015-000003_bb0115","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1158\/1078-0432.CCR-10-0421","article-title":"Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1\/2 inhibitors in cancer patients","volume":"16","author":"Nardone","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1136\/esmoopen-2015-000003_bb0120","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1517\/14740338.2014.904283","article-title":"Targeting the epidermal growth factor receptor in solid tumors: focus on safety","volume":"13","author":"Lucchini","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"10.1136\/esmoopen-2015-000003_bb0125","first-page":"1079","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1136\/esmoopen-2015-000003_bb0130","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/bjc.2011.237","article-title":"Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck","volume":"105","author":"Del Campo","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1136\/esmoopen-2015-000003_bb0135","first-page":"245","article-title":"Targeted treatment of head and neck squamous-cell carcinoma: potential of lapatinib","volume":"7","author":"Gandhi","year":"2014","journal-title":"Onco Targets Ther"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292032593X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292032593X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/esmoopen-2015-000003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:19:11Z","timestamp":1761855551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205970292032593X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"alternative-id":["S205970292032593X"],"URL":"https:\/\/doi.org\/10.1136\/esmoopen-2015-000003","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/esmoopen-2015-000003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.","name":"copyright","label":"Copyright"}],"article-number":"e000003"}}